Medtronic Announces FDA Approval of Next-Gen TAVR System for Treatment of Symptomatic Severe Aortic Stenosis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Medtronic, Inc. (MDT) PT Raised to $155 at Jefferies
August 25, 2021 7:30 AM EDTJefferies analyst Raj Denhoy raised the price target on Medtronic, Inc. (NYSE: MDT) to $155.00 (from $145.00) while maintaining a Buy rating.
The analyst commented, "MDT posted a ~$120mn/$0.10 beat on out-performance in MedSurg on elective procedure recovery, share gains in Cardio/Micra,... More
Medtronic, Inc. (MDT) PT Raised to $145 at Stifel
August 25, 2021 6:33 AM EDTStifel analyst Rick Wise raised the price target on Medtronic, Inc. (NYSE: MDT) to $145.00 (from $140.00) while maintaining a Buy rating.
The analyst commented, "Despite some signs of new COVID-related slowdowns in late-July, Medtronic did start the F2022 year with a better-than-expected overall performance. Nicely-exceeding Stifel/Consensus estimates (Sales: $7.866B/$7.871B; EPS: $1.32), Medtronic reported F1Q sales... More
